STOCKHOLM, Oct. 5, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announcedthe publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with MOB-015 was achieved across the full range of baseline terbinafine susceptibility, including in patients with reduced in vitro susceptibility.

The analyses are based on data from the previously completed North American Phase 3 study evaluating daily treatment with MOB-015 for 48 weeks. The analyses included 506 dermatophyte isolates from onychomycosis patients. Only 3.2% baseline isolates showed elevated MIC values (≥0.5 µg/ml). Among MOB-015-treated patients with evaluable end-of-study results, 74.3% achieved mycological cure, including two of three patients with elevated baseline MIC values.

The work was conducted in collaboration with Professor Mahmoud Ghannoum at Case Western Reserve University in Cleveland, Ohio.

"These results are encouraging, particularly given the increasing attention to antifungal resistance. Terbinafine showed potent activity against the vast majority of isolates, and MOB-015 achieved mycological cure across the full range of baseline susceptibility. The findings further strengthen the scientific foundation for MOB-015," says Amir Tavakkol, CSO of Moberg Pharma.

The article, 'In Vitro Terbinafine Susceptibility of Dermatophytes and Mycological Cure Outcomes from a Multicenter Phase III Onychomycosis Trial', is published in Journal of Fungi, 2026, 12(10), 739 and is available here.

For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se

About this information
The information was released for public distribution through the contact named above, on October 5^th, 2026, at 8:00 am CEST.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 14 countries. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. MOB-015 is sold in Sweden, Norway and Israel under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe, APAC, Canada and China. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/new-analyses-on-terbinafine-susceptibility-and-mob-015-published-in-journal-of-fungi,c4404268

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/new-analyses-on-terbinafine-susceptibility-and-mob-015-published-in-journal-of-fungi-302898140.html

SOURCE Moberg Pharma